title: Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis.
abstract: Oxidative stress and neuronal energy depletion are characteristic biochemical hallmarks of Alzheimer's disease (AD). It is therefore conceivable that pro-energetic and antioxidant drugs such as alpha-lipoic acid might delay the onset or slow down the progression of the disease. In a previous study, 600mg alpha-lipoic acid was given daily to nine patients with AD (receiving a standard treatment with choline-esterase inhibitors) in an open-label study over an observation period of 12 months. The treatment led to a stabilization of cognitive functions in the study group, demonstrated by constant scores in two neuropsychological tests (the mini mental state exam, MMSE and the Alzheimer's disease assessment score cognitive subscale, ADAScog). In this report, we have extended the analysis to 43 patients over an observation period of up to 48 months. In patients with mild dementia (ADAScog < 15), the disease progressed extremely slowly (ADAScog: +1.2 points/year, MMSE: -0.6 points/year), in patients with moderate dementia at approximately twice the rate. However, the progression appears dramatically lower than data reported for untreated patients or patients on choline-esterase inhibitors in the second year of long-term studies. Despite the fact that this study was not double-blinded, placebo-controlled and randomized, our data suggest that treatment with alpha-lipoic acid might be a successful 'neuroprotective' therapy option for AD. However, a state-of-the-art phase II trial is needed urgently.
authors.affiliation: Department of Medical Rehabilitation and Geriatrics, Henriettenstiftung, Hannover, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Hager
authors.forename: M
authors.initials: M
authors.lastname: Kenklies
authors.forename: J
authors.initials: J
authors.lastname: McAfoose
authors.forename: J
authors.initials: J
authors.lastname: Engel
authors.forename: G
authors.initials: G
authors.lastname: Münch
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D000975:Antioxidants / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy*; D018450:Disease Progression; D000077265:Donepezil; D005260:Female; D005500:Follow-Up Studies; D005702:Galantamine / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000627:therapeutic use; D008134:Long-Term Care; D008297:Male; D008609:Mental Status Schedule; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D010880:Piperidines / Q000627:therapeutic use; D008063:Thioctic Acid / Q000627:therapeutic use*
chemical_list: D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D005702:Galantamine; D008063:Thioctic Acid; D000077265:Donepezil